Use of Moderate‐Intensity Statins for Low‐Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. Issue 4 (9th July 2017)

• Record Type: Journal Article
• Authors: Kim, Hun‐Sung; Lee, Hyeseon; Lee, Sue Hyun; Jeong, Yoo Jin; Kim, Tong Min; Yang, So Jung; Baik, Sun Jung; Kim, Hyunah; Lee, Seung‐Hwan; Cho, Jae Hyoung; Choi, In‐Young; Yoon, Kun‐Ho; Kim, Ju Han
• Is Part Of: Basic & clinical pharmacology & toxicology. Volume 121:Issue 4(2017)
• Page Start: 272
• Page End: 278
• Publication Date: 2017-07-09
• Subjects: Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology, Clinical -- Periodicals; Computer network resources; Electronic journals; 615.1
• DOI: 10.1111/bcpt.12765
• Languages: English
• ISSNs: 1742-7835

Abstract

Abstract: The ACC/AHA 2013 guideline recommends high‐intensity statin therapy for a decrease in low‐density lipoprotein cholesterol (LDL‐C) level by >50% among patients with baseline values of ≥190 mg/dL (approximately 4.872 mmol/L); however, this value should be modified before applying it to Korean populations. We investigated the statin‐specific LDL‐C‐lowering effects in Korean patients with baseline LDL‐C value ≥4.872 mmol/L. Data of patients prescribed a statin for the first time from January 2009 to December 2013 were assessed. In patients with baseline LDL‐C value ≥4.872 mmol/L, laboratory data for a maximum of 6 months from the date of first statin prescription were collected. Among 33, 721 patients who were prescribed a statin for the first time, 655 patients had a baseline LDL‐C value ≥4.872 mmol/L (1.9%). Of these, 179 patients were analysed. Patients receiving moderate‐intensity statins were divided into two groups based on LDL‐C reduction rate ( p = 0.0002), defined as moderate–high‐intensity (atorvastatin 20 mg, rosuvastatin 10 mg, simvastatin 20 mg) and moderate–low‐intensity (atorvastatin 10 mg, pitavastatin 2 mg, pravastatin 40 mg) statin groups. LDL‐C reduction rates did not significantly differ between the moderate–high‐ and high‐intensity statin groups ( p = 0.4895). We found that some moderate‐intensity statins demonstrated a LDL‐C‐lowering effect of more than 50% in Korean patients with a baseline LDL‐C value ≥4.872 mmol/L. Our results reflect the need of a large‐scale, randomized, controlled trial on partial reclassification of statins for patients with baseline LDL‐C value ≥4.872 mmol/L before adopting ACC/AHC guidelines in Korea.